However, a recent randomized phase 3 clinical study showed no benefit from bevacizumab in patients with pancreatic cancer. Thus, new antiangiogenic approaches are needed to treat this disease. Our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback